Trial Profile
A Phase III Study of CS-8958 (Postexposure Prophylaxis) -A randomized, double-blind, placebo-controlled, confirmative study of CS-8958 for prevention of influenza-
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 27 May 2016 New trial record